Adverse Event Reporting for Compounded Drugs

News
Article

FDA issued a statement about the importance of reporting adverse events resulting from the use of compounded drugs.

Janet Woodcock, MD, director of FDA’s Center for Drug Evaluation and Research, issued a statement on Sept. 9, 2019 stressing the importance of adverse events reporting regarding the use of compounded drugs. Woodcock also announced that FDA will be taking steps to improve adverse event reporting and analysis.

Outsourcing facilities are required to report adverse events to FDA and include information about these events on compounded drug labeling. Along with agency inspections, FDA relies on adverse event reporting to alert the agency of any potential health threats regarding the use of a compounded drug. In her statement, Woodcock described a situation in which more than 4000 adverse events found during an inspection of a compounder of hormone products were never reported to FDA. These adverse events indicated that the compounded products may possibly be associated with serious health risks, including cancer. However, the information regarding the events was never reported to the agency.

As a result of this case, and others, FDA is taking steps to work with outsourcing facilities to improve the reporting of adverse events. The agency is also working with state regulatory partners to investigate adverse event complaints. In addition, the National Academy of Sciences, Engineering, and Medicine (NASEM) will be conducting a study on the risks associated with compounded hormone products.

“Because compounding can serve an important role for patients whose medical needs cannot be met by an FDA-approved drug, we must work to protect patients from the risk of contaminated or otherwise harmful products. As we develop our policy and oversight program, the FDA continually strives to strike a balance between preserving access to compounded drugs for patients who have a medical need for them while protecting patients from the risks associated with compounded drugs that are not made in accordance with applicable quality standards or other requirements,” Woodcock said in the statement.

Source: FDA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Related Content